Big Cypress Acquisition Corp.
Status: Deal Closed
U=S+W/2
W=S@11.5
| IPO Proceeds, $M | $115.00M |
|---|---|
| IPO Date | Jan 12, 2021 |
| CEO | Samuel J. Reich |
| Left Lead | Ladenburg Thalmann |
| IPO Cash in Trust | 101.0% |
| SPAC Tenor | 15+(3*2) |
| IPO Sector |
Healthcare
Life sciences |
| IPO Geography | Global |
| Target Company | SAB Biotherapeutics |
| Deal Announced | Jun 22, 2021 |
| Deal Size, $M | $325.38M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Oct 20, 2021 |
| Amendment Vote | TBD |
| Closing Date | Oct 22, 2021 |
Formerly BCYP
SABS
SABSW
| Price | $2.89 $0.29 |
|---|---|
| Last closing price | $2.81 |
| H/L, 52-week | $0.37 / $1.45 |
| Volume, today | 20,386 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Big Cypress Acquisition Corp.:
- Structure and cap table
- 5 directors & officers
- 23 filings and events
- 2 underwriters
- 3 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Samuel J. Reich | 45 | CEO, CFO and Director |
| Jeffrey G. Spragens | 70 | Chairman |
| James Martin | 54 | Director |
| Ilan Katz | 48 | Director |
| Stephen D. Collins, MD, PhD. | 68 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Ladenburg Thalmann | Joint BR | 9,000,000 | units |
| Brookline Capital Markets | Joint BR | 1,000,000 | |
| 10,000,000 | units | ||
| Up-Front UW fee | 1.33 | % | |
| Deferred UW fee |
3.67 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.